Background Ivacaftor (IVA) has been shown to improve lung function and other clinical outcomes in people with cystic fibrosis (CF). A decade of real-world IVA availability has enabled the examination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback